Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals

被引：0
|
作者：
Colmenares, Alejandro [1 ]
Galvis, Clara [1 ]
Cabrales, Lina [1 ]
Ibata, Linda [1 ]
Marulanda, Juliana [2 ]
Ovalle, Oscar [2 ]
Puello, Dionisio [3 ]
Rojas, Catherine [4 ]
Africano, Martha [5 ]
Ballesteros, Adriana [6 ]
Posso, Hector [7 ]
机构：
[1] Hosp Mil Cent, Bogota, Colombia
[2] Clin Materno Infantil, Bogota, Colombia
[3] Cin Crecer, Cartagena, Colombia
[4] Ctr Policlin Olaya, Bogota, Colombia
[5] Clin San Luis, Bucaramanga, Colombia
[6] Fdn Valle Lili, Cali, Colombia
[7] Hosp Mil Cent, Cali, Colombia
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA2776
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals
    Galvis, Clara
    Colmenares, Alejandro
    Cabrales, Lina
    Ibata, Linda
    Marulanda, Juliana
    Ovalle, Oscar
    Puello, Dionisio
    Rojas, Catherine
    Africano, Martha
    Ballesteros, Adriana
    Posso, Hector
    [J]. PEDIATRIC PULMONOLOGY, 2022, 57 (10) : 2420 - 2427
  • [2] Respiratory syncytial virus: Early immunoprophylaxis in NICU preterm infants using palivizumab
    Bonaparte, J
    Wu, SY
    Pyati, S
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 311A - 311A
  • [3] Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
    Abushahin, Ahmad
    Janahi, Ibrahim
    Tuffaha, Amjad
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2018, 11 : 41 - 46
  • [4] Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia
    Gabriel Pineros, Juan
    De la Hoz-Valle, Jose
    Galvis, Clara
    Celis, Astrid
    Ovalle, Oscar
    Cecilia Sandoval, Carmen
    Orrego, Jaime
    Vides, Saby
    Rojas, Iader
    Bustamante, Hernando
    Gallon, Carlos
    Alberto Mesa, Jaime
    [J]. JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (11): : 1708 - 1713
  • [5] Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32-35 Weeks Gestation Not Receiving Immunoprophylaxis
    Ambrose, Christopher S.
    Anderson, Evan J.
    Simoes, Eric A. F.
    Wu, Xionghua
    Elhefni, Hanaa
    Park, C. Lucy
    Sifakis, Frangiscos
    Groothuis, Jessie R.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (06) : 576 - 582
  • [6] Impact of palivizumab on expected costs of respiratory syncytial virus infection int preterm infants: Potential for savings
    Marchetti, A
    Lau, W
    Magar, R
    Wang, LP
    Devercelli, G
    [J]. CLINICAL THERAPEUTICS, 1999, 21 (04) : 752 - 766
  • [7] Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
    Resch, Bernhard
    Egger, Beatrice
    Kurath-Koller, Stefan
    Urlesberger, Berndt
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 57 : 50 - 53
  • [8] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [9] Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab
    Lavoie, Pascal M.
    Solimano, Alfonso
    Taylor, Richard
    Kwan, Eddie
    Claydon, Jennifer
    Turvey, Stuart E.
    Marr, Nico
    [J]. JAMA PEDIATRICS, 2016, 170 (02) : 174 - 176
  • [10] Immunoprophylaxis with palivizumab for prevention of Respiratory Syncytial Virus infection: Indications for use and preliminary data
    Vagnarelli, F
    Vancini, A
    Mariani, S
    Magnani, C
    Banchini, G
    [J]. PERINATOLOGY 2001, VOLS 1 AND 2, 2001, : 1001 - 1003
12345